Mei Wu - Genentech, Inc | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 15 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Care Coordination for Mosunetuzumab Therapy in Patients with Follicular Lymphoma in Community Practices: Learnings from the MorningSun Study Investigators

Tara Graff,Ian Flinn, Jeff P Sharman, Steven Liu, Bertrand M Anz,Mitul Gandhi, Ayed,Richard Zuniga, Abdul Hai Mansoor, Lourenia M Cassoli,Mei Wu, Prachi Jani, Juliana M L Biondo, Tony Lin,John M Burke

Cancer medicineno. 11 (2025): e70936-e70936

Cited0Views0WOSBibtex

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma after Two or More Lines of Systemic Therapy in the USA

Shih-Wen Lin,Sheila Shapouri,Hélène Parisé, Eric Bercaw,Mei Wu,Eunice Kim,Matthew Matasar

PharmacoEconomicspp.1-14, (2024)

Cited1Views0WOSBibtex

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma over a Long-Term Horizon in the United States

Matthew Matasar, Katherine L Rosettie, Almut Mecke,Danilo Di Maio,Shih-Wen Lin,Mei Wu, Esprit Ma

Bloodno. Supplement 1 (2024): 3648-3648

Cited0Views0Bibtex

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Matthew Matasar, Katherine L. Rosettie,Shih-Wen Lin,Mei Wu, Esprit Ma

BLOOD（2024）

Cited0Views0Bibtex

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy is Associated with Changes in Lymphocyte Counts

Elise A. Chong,Elicia Penuel,Nancy L. Bartlett,Francesc Bosch,L. Elizabeth Budde,Keith Fay,Ian W. Flinn,Andre Goy,Anita Kumar, Rachel Lundberg,Ellen B. Napier,Loretta J. Nastoupil,Mazyar Shadman,Michael C. Wei,Mei Wu,Shen Yin,Emeline R. Chong,Stephen J. Schuster

BLOOD (2023)

Cited0Views0Bibtex

Subcutaneous Mosunetuzumab is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn,L. Elizabeth Budde,Aung M. Tun,John M. Burke,Bertrand Anz, Shachar Peles,Jeff P. Sharman,Praveen K. Tumula,Juliana M. L. Biondo, Prachi Jani,Mei Wu, Tony Lin, Neha Parmar,Yong Mun,Nai-Shun Yao, Steven Liu

BLOOD（2023）

Cited1Views0Bibtex

Mosunetuzumab Safety Profile in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial

Matthew Matasar,Nancy L. Bartlett,Mazyar Shadman,Lihua E. Budde,Ian Flinn,Gareth P. Gregory,Won Seog Kim,Georg Hess,Dima El-Sharkawi,Catherine S. Diefenbach, Huang,Iris To,Joana Parreira,Mei Wu,Antonia Kwan,Sarit Assouline

Clinical lymphoma, myeloma & leukemia（2023）

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn